Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Turnidge

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
Jac-Antimicrobial Resistance|July 5, 2021
Feasibility of de-linking reimbursement of antimicrobials from sales: the Australian perspective as a qualitative case studyNadine T Hillock, Tracy L Merlin, Jonathan Karnon, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2007
Selection of SHV extended-spectrum-beta-lactamase-dependent cefotaxime and ceftazidime resistance in Klebsiella pneumoniae requires a plasmid-borne blaSHV geneDavid S Hammond, Tegan Harris, Jan Bell, et al.
International Journal of Technology Assessment in Health Care|November 3, 2020
Value assessment of antimicrobials and the implications for development, access, and funding of effective treatments: Australian stakeholder perspectiveNadine T Hillock, Tracy L Merlin, Jonathan Karnon, et al.
Australian Health Review : a Publication of the Australian Hospital Association|July 6, 2019
Clinical indications treated with unregistered antimicrobials: regulatory challenges of antimicrobial resistance and access to effective treatment for patientsNadine T Hillock, Lisa Paradiso, John Turnidge, et al.
Emerging Infectious Diseases|August 31, 2012
Control of fluoroquinolone resistance through successful regulation, AustraliaAllen C Cheng, John Turnidge, Peter Collignon, et al.
Communicable Diseases Intelligence Quarterly Report|June 17, 2003
TSN Database Australia, a new tool to monitor antimicrobial resistance in AustraliaJohn Turnidge, Laurence R McCarthy, Ronald N Master, et al.
The Journal of Antimicrobial Chemotherapy|January 9, 2014
Carbapenemase-producing bacteria in companion animals: a public health concern on the horizonSam Abraham, Hui San Wong, John Turnidge, et al.
The Journal of Antimicrobial Chemotherapy|May 6, 2021
Comparative macrolide use in humans and animals: should macrolides be moved off the World Health Organisation's critically important antimicrobial list?Darren J Trott, John Turnidge, Jessica H Kovac, et al.
Applied Health Economics and Health Policy|January 14, 2026
Estimation of 'spectrum value': A discrete choice experiment to investigate the willingness-to-pay for narrow-spectrum based on other antimicrobial characteristicsNadine T Hillock, Gang Chen, Tracy L Merlin, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|June 20, 2020
Utilising sigmoid models to predict the spread of antimicrobial resistance at the country levelNoga Fallach, Yaakov Dickstein, Erez Silberschein, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Jac-Antimicrobial Resistance|July 5, 2021
Feasibility of de-linking reimbursement of antimicrobials from sales: the Australian perspective as a qualitative case studyNadine T Hillock, Tracy L Merlin, Jonathan Karnon, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2007
Selection of SHV extended-spectrum-beta-lactamase-dependent cefotaxime and ceftazidime resistance in Klebsiella pneumoniae requires a plasmid-borne blaSHV geneDavid S Hammond, Tegan Harris, Jan Bell, et al.
International Journal of Technology Assessment in Health Care|November 3, 2020
Value assessment of antimicrobials and the implications for development, access, and funding of effective treatments: Australian stakeholder perspectiveNadine T Hillock, Tracy L Merlin, Jonathan Karnon, et al.
Australian Health Review : a Publication of the Australian Hospital Association|July 6, 2019
Clinical indications treated with unregistered antimicrobials: regulatory challenges of antimicrobial resistance and access to effective treatment for patientsNadine T Hillock, Lisa Paradiso, John Turnidge, et al.
Emerging Infectious Diseases|August 31, 2012
Control of fluoroquinolone resistance through successful regulation, AustraliaAllen C Cheng, John Turnidge, Peter Collignon, et al.
Communicable Diseases Intelligence Quarterly Report|June 17, 2003
TSN Database Australia, a new tool to monitor antimicrobial resistance in AustraliaJohn Turnidge, Laurence R McCarthy, Ronald N Master, et al.
The Journal of Antimicrobial Chemotherapy|January 9, 2014
Carbapenemase-producing bacteria in companion animals: a public health concern on the horizonSam Abraham, Hui San Wong, John Turnidge, et al.
The Journal of Antimicrobial Chemotherapy|May 6, 2021
Comparative macrolide use in humans and animals: should macrolides be moved off the World Health Organisation's critically important antimicrobial list?Darren J Trott, John Turnidge, Jessica H Kovac, et al.
Applied Health Economics and Health Policy|January 14, 2026
Estimation of 'spectrum value': A discrete choice experiment to investigate the willingness-to-pay for narrow-spectrum based on other antimicrobial characteristicsNadine T Hillock, Gang Chen, Tracy L Merlin, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|June 20, 2020
Utilising sigmoid models to predict the spread of antimicrobial resistance at the country levelNoga Fallach, Yaakov Dickstein, Erez Silberschein, et al.
Pageof 9